Abstract
ObjectivesARIEL3 is a placebo-controlled randomized trial of the PARP inhibitor (PARPi) rucaparib as maintenance treatment in HGOC patients who responded to the latest line of platinum therapy (NCT01968213). Rucaparib improved...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have